- Home
- TSI vs MIRM Comparison
TSI vs MIRM Comparison
Compare TSI & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSI
- MIRM
- Stock Information
- Founded
- TSI 1987
- MIRM 2018
- Country
- TSI United States
- MIRM United States
- Employees
- TSI N/A
- MIRM N/A
- Industry
- TSI Investment Managers
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- TSI Finance
- MIRM Health Care
- Exchange
- TSI Nasdaq
- MIRM Nasdaq
- Market Cap
- TSI 234.6M
- MIRM 2.5B
- IPO Year
- TSI N/A
- MIRM 2019
- Fundamental
- Price
- TSI $4.91
- MIRM $50.30
- Analyst Decision
- TSI
- MIRM Strong Buy
- Analyst Count
- TSI 0
- MIRM 9
- Target Price
- TSI N/A
- MIRM $66.22
- AVG Volume (30 Days)
- TSI 106.8K
- MIRM 468.1K
- Earning Date
- TSI 01-01-0001
- MIRM 08-06-2025
- Dividend Yield
- TSI 7.46%
- MIRM N/A
- EPS Growth
- TSI N/A
- MIRM N/A
- EPS
- TSI N/A
- MIRM N/A
- Revenue
- TSI N/A
- MIRM $379,251,000.00
- Revenue This Year
- TSI N/A
- MIRM $35.83
- Revenue Next Year
- TSI N/A
- MIRM $16.83
- P/E Ratio
- TSI N/A
- MIRM N/A
- Revenue Growth
- TSI N/A
- MIRM 69.31
- 52 Week Low
- TSI $4.48
- MIRM $33.52
- 52 Week High
- TSI $4.87
- MIRM $54.23
- Technical
- Relative Strength Index (RSI)
- TSI 44.20
- MIRM 59.09
- Support Level
- TSI $4.87
- MIRM $47.89
- Resistance Level
- TSI $4.99
- MIRM $51.93
- Average True Range (ATR)
- TSI 0.05
- MIRM 1.49
- MACD
- TSI -0.01
- MIRM -0.25
- Stochastic Oscillator
- TSI 42.11
- MIRM 59.65
About TSI TCW Strategic Income Fund Inc.
Tcw Strategic Income Fund Inc operates as a closed-end management investment company. Its investment objective is to seek a total return comprised of current income and capital appreciation by investing in a wide range of securities. The company invests in a range of industries, such as airlines, banks, beverages, biotechnology, chemicals, computers, diversified financial services, entertainment and others.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.